Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers

Journal of Gastroenterology

Volumn 50, Issue 2, 2015, Pages 167-179

  Mira Pascual, L ^a   Cabrera Rubio, R ^b   Ocon, S ^c   Costales, P ^c   Parra, A ^d   Suarez, A ^d   Moris, F ^c   Rodrigo, L ^d   Mira, A ^b   Collado, M C ^a  

^a INSTITUTO DE AGROQUÍMICA Y TECNOLOGÍA DE ALIMENTOS CSIC   (Spain)

^b Center for Advanced Research in Public Health   (Spain)

^c Edificio Científico Tecnológico ^*  (Spain)

^d Central University Hospital of Asturias   (Spain)

Author keywords

Adenocarcinoma; Adenoma; Archaea; Bacteria; Colorectal cancer (CRC); Feces; Microbiota; Mucosal tissue

Indexed keywords

RNA 16S;

ADENOCARCINOMA; ADENOMA; ADOLESCENT; ADULT; AGED; ARCHAEON; BACTERIUM; CASE CONTROL STUDY; COLON; COLORECTAL TUMOR; DISEASE COURSE; FECES; FEMALE; GENETICS; HUMAN; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; VERY ELDERLY;

ADENOCARCINOMA; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARCHAEA; BACTERIA; CASE-CONTROL STUDIES; COLON; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FECES; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MICROBIOTA; MIDDLE AGED; RNA, RIBOSOMAL, 16S;

EID: 84937161675     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-014-0963-x     Document Type: Article

References (56)

1. Cunningham D, Atki W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet. 2010;375:1030–47.
2. Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, et al. Colonoscopy in colorectal cancer screening for detection of advanced neoplasia. N Engl J Med. 2006;355:1863–72.
3. Bamia C, Lagiou P, Buckland G, Grioni S, Agnoli C, Taylor AJ, et al. Mediterranean diet and colorectal cancer risk: results form a European cohort. Eur J Epidemiol. 2013;28:317–28.
4. Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault ML, Van Nhieu JT, et al. Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol. 2013;6:215–29.
5. Gaboriau-Routhiau V, Lécuyer E, Cerf-Bensussan N. Role of microbiota in postnatal maturation of intestinal T-cell responses. Curr Opin Gastroenterol. 2011;27(6):502–8.
6. O’Keefe SJ, Chung D, Mahmoud N, Sepulveda AR, Manafe M, et al. Why do African Americans get more colon cancer than Native Africans? J Nutr. 2007;137:S75–82.
7. Man SM, Kaakoush NO, Mitchell HM. The role of bacteria and pattern-recognition receptor’s in Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2011;8:152–68.
8. Candela M, Guidotti M, Fabbri A, Brigidi P, Franceschi C, Fiorentini C. Human intestinal microbiota: cross talk with the host and its potential role in colorectal cancer. Crit Rev Micro. 2011;37:1–14.
9. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;21:198–213.
10. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179–85.
11. Marchesi JR, Dutilh BE, Hall N, Peters WHM, Roelofs R, et al. Towards the human colorectal cancer microbiome. PLoS ONE. 2011;6(5):e20447.
12. Hu B, Elinav E, Huber S, Strowig T, Hao L, Hafemann A, et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. PNAS. 2013;110(24):9682–7.
13. Sobhani I, Tap J, Roudot-Thoraval F, Roperch JP, Letulle S, Langella P, Corthier G, Tran Van Nhieu J, Furet JP. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS ONE. 2011;6(1):e16393.
14. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS ONE. 2012;7(6):e39743.
15. Scanlan PD, Shanahan F, Clune Y, Collins JK, O’Sullivan GC, O’Riordan M, et al. Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol. 2008;10:789–98.
16. Parkin D. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.
17. Castellarin M, Warren R, Freeman J, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299–306.
18. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004;54(Pt 5):1469–76.
19. Scanlan PD, Shanahan F, Marchesi JR. Human methanogen diversity and incidence in healthy and diseased colonic groups using mcrA gene analysis. BMC Microbiol. 2008;20(8):79.
20. Azcárate-Peril MA, Sikes M, Bruno-Bárcena JM. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol. 2011;301(3):G401–24.
21. Cabrera-Rubio R, Garcia-Núñez M, Setó L, Antó JM, Moya A, Monsó E, Mira A. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol. 2012;50:3562–8.
22. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75(23):7537–41.
23. Cole JR, Wang Q, Cardenas E, Fish J, Chai B, Farris RJ, et al. The ribosomal database project: improved alignments and new tools for rRNA analysis. Nucleic Acids Res. 2009;37:D141–5.
24. Yarza P, Richter M, Peplies J, Euzeby J, Amann R, Schleifer K, et al. The all-species living tree PROJECT: a 16S rRNA-based phylogenetic tree of all sequenced type strains. Syst Appl Microbiol. 2008;31:241–50.
25. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71(12):8228–35.
26. Collado MC, Isolauri E, Laitinen K, Salminen S. Distinct composition of gut microbiota during pregnancy in overweight and normal-weight women. Am J Clin Nutr. 2008;88:894–9.
27. Yu Y, Lee C, Kim J, Hwang S. Group-specific primer and probe sets to detect methanogenic communities using quantitative real-time polymerase chain reaction. Biotechnol Bioeng. 2005;89(6):670–9.
28. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14(2):207–15.
29. Turner ND, Ritchie LE, Bresalier RS, Chapkin RS. The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis. Curr Gastroenterol Rep. 2013;15(9):346.
30. Vipperia K, O’Keefe SJ. The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr Clin Practice. 2013;27:624–35.
31. Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013;66(2):462–70.
32. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn’s disease and ulcerative colitis patients. J Med Microbiol. 2006;55:1141–9.
33. Ohigashi S, Sudo K, Kobayashi D, Takahashi T, Nomoto K, Onodera H. Significant changes in the intestinal environment after surgery in patients with colorectal cancer. J Gastrointest Surg. 2013;17(9):1657–64.
34. Geng J, Fan H, Tang X, Zhai H, Zhang Z. Diversified pattern of the human colorectal cancer microbiome. Gut Pathog. 2013;5(1):2.
35. Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23(8 Pt 1):1298–303.
36. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 2012;6(2):320–9.
37. Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol. 2008;14(3):390–400.
38. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE. 2013;8(8):e70803.
39. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2011;22(2):299–306.
40. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2011;22(2):292–8.
41. McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS ONE. 2013;8(1):e53653.
42. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470–81.
43. Kalliomäki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants developing or not developing atopy. J Allergy Clin Immunol. 2001;107:129–34.
44. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7.
45. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495–549.
46. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3(4):279–88.
47. Lyra A, Lahtinen S, Ouwehand AC. Gastrointestinal benefits of probiotics: clinical evidence. In: Salminen S, von Wright A, Lahtinen S, Ouwehand A, editors. Lactic acid bacteria: microbiological and functional aspects. 4th ed. Boca Raton: CRC Press; 2012. p. 509–23.
48. Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: role in chemoprevention for colorectal cancer? Cancer Biol Ther. 2006;5(10):1265–9.
49. Collado MC, Isolauri E, Salminen S, Sanz Y. The impact of probiotic on gut health. Curr Drug Metab. 2009;10(1):68–78.
50. Abell GCJ, Conlon MA, McOrist AL. Methanogenic archaea in adult human faecal samples are inversely related to butyrate concentration. Microb Ecol Health Dis. 2006;18:154–60.
51. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science. 2005;308:1635–8.
52. Mathur R, Amichai M, Chua KS, Mirocha J, Barlow GM, Pimentel M. Methane and hydrogen positivity on breath test is associated with greater body mass index and body fat. J Clin Endocrinol Metab. 2013;98(4):E698–702.
53. Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, et al. Correlation between body mass index and gut concentrations of Lactobacillusreuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichiacoli. Int J Obes (Lond). 2013;37(11):1460–6.
54. Florin TH. Alkyl halides, super hydrogen production and the pathogenesis of pneumatosis cystoides coli. Gut. 1997;41:778–84.
55. Pique JM, Pallares M, Cuso E, Vilar-Bonet J, Gassull MA. Methane production and colon cancer. Gastroenterology. 1984;87:601–5.
56. Holma R, Osterlund P, Sairanen U, Blom M, Rautio M, Korpela R. Colonic methanogenesis in vivo and in vitro and fecal pH after resection of colorectal cancer and in healthy intact colon. Int J Colorectal Dis. 2012;27(2):171–8.